用于治疗胰岛自身免疫的耐受性纳米颗粒。
Tolerogenic Nanoparticles to Treat Islet Autoimmunity.
作者信息
Neef Tobias, Miller Stephen D
机构信息
Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Feinberg School of Medicine, Northwestern University, 6-713 Tarry Building, 303 E. Chicago Avenue, Chicago, IL, 60611, USA.
出版信息
Curr Diab Rep. 2017 Aug 8;17(10):84. doi: 10.1007/s11892-017-0914-z.
PURPOSE OF REVIEW
The current standard therapy for type 1 diabetes (T1D) is insulin replacement. Autoimmune diseases are typically treated with broad immunosuppression, but this has multiple disadvantages. Induction of antigen-specific tolerance is preferable. The application of nanomedicine to the problem of T1D can take different forms, but one promising way is the development of tolerogenic nanoparticles, the aim of which is to mitigate the islet-destroying autoimmunity. We review the topic and highlight recent strategies to produce tolerogenic nanoparticles for the purpose of treating T1D.
RECENT FINDINGS
Several groups are making progress in applying tolerogenic nanoparticles to rodent models of T1D, while others are using nanotechnology to aid other potential T1D treatments such as islet transplant and islet encapsulation. The strategies behind how nanoparticles achieve tolerance are varied. It is likely the future will see even greater diversity in tolerance induction strategies as well as a greater focus on how to translate this technology from preclinical use in mice to treatment of T1D in humans.
综述目的
1型糖尿病（T1D）目前的标准治疗方法是胰岛素替代疗法。自身免疫性疾病通常采用广泛的免疫抑制进行治疗，但这种方法存在多种弊端。诱导抗原特异性耐受更为可取。纳米医学应用于T1D问题可以采取不同形式，但一种有前景的方法是开发耐受性纳米颗粒，其目的是减轻破坏胰岛的自身免疫反应。我们对该主题进行综述，并重点介绍为治疗T1D而生产耐受性纳米颗粒的最新策略。
最新发现
几个研究小组在将耐受性纳米颗粒应用于T1D啮齿动物模型方面取得了进展，而其他研究小组则在利用纳米技术辅助其他潜在的T1D治疗方法，如胰岛移植和胰岛封装。纳米颗粒实现耐受的背后策略多种多样。未来，耐受诱导策略可能会更加多样化，同时也会更加关注如何将这项技术从小鼠的临床前应用转化为人类T1D的治疗。
Zotero 插件